Compare Duolingo Inc (DUOL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs TransMedics Group Inc — how do they compare? Duolingo Inc trades at $149.58 (market cap $7.08B), while TransMedics Group Inc trades at $78.41 (market cap $2.74B). The key difference: Duolingo Inc is far larger — about 2.6× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 729,171). Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and TransMedics Group Inc for 24 Days on average.
| DUOL | TMDX | |
|---|---|---|
Market Cap | $7.08B | $2.74B |
Volume | 729,171 | 949,331 |
Sector | Technology | Health |
52-Week High | $341.08 | $150.42 |
52-Week Low | $90.03 | $61.99 |
Typical Hold Time | 137 Days | 24 Days |
Enterprise Value | $5.85B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.16, down 0.37% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamental momentum with Q2 2026 EPS of $0.66 beating expectations of $0.604, marking the third consecutive quarterly beat. Revenue growth remains robust at 29% year-over-year, supported by a 36% net income margin. Technical indicators show a bullish trend with the stock trading above key support levels, though RSI suggests potential near-term overbought conditions.
Duolingo's outlook remains positive with accelerating revenue growth and expanding profitability, though the stock trades at a premium valuation with a P/E of 17.87. Key risks include CEO share sales and competitive pressures in the edtech space. Analyst consensus leans cautious with 37.5% buy ratings versus 54.2% hold, suggesting potential for re-rating if growth momentum continues.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
